Ascendis Pharma A (ASND) Total Liabilities (2012 - 2026)

Ascendis Pharma A has reported Total Liabilities for 15 years, with the latest figure at $1.8 billion in Q1 2026.

• Quarterly Total Liabilities rose 34.79% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 34.79% YoY) and the FY2025 annual result came in at $1.7 billion, up 24.2% from the prior year.
• Total Liabilities advanced to $1.8 billion in Q1 2026 per ASND's latest filing, from $1.7 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $1.8 billion in Q1 2026 and troughed at $767.2 million in Q2 2022.
• A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 303.36% in 2022, then gained 7.73% in 2023.
• Over 5 years, Total Liabilities stood at $843.1 million in 2022, then gained by 23.95% to $1.0 billion in 2023, then jumped by 31.42% to $1.4 billion in 2024, then climbed by 24.2% to $1.7 billion in 2025, then grew by 4.0% to $1.8 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.8 billion, $1.7 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.